4.03  0.03 (0.75%)		07-19 15:14
Open: 4.0925 High: 4.14 Volume: 4,533		Pre. Close: 4 Low: 4 Market Cap: 58(M)

Short term
Mid term
Targets	6-month :	12.95	1-year :	15.12
Resists	First :	11.09	Second :	12.95
Pivot price	10.42
Supports	First :	9.71	Second :	8.85
MAs	MA(5) :	10.57	MA(20) :	10.47
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	79.3	D(3) :	64.5
RSI	RSI(14): 60.9
52-week	High :	11.54	Low :	7.84

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ BTSG ] has closed below upper band by 1.9%. Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	10.81 - 10.84	10.84 - 10.87
Low:	10.44 - 10.48	10.48 - 10.53
Close:	10.71 - 10.77	10.77 - 10.84

Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company is engaged in developing Biostage Esophageal Implant for the treating esophageal cancer. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.

Sun, 10 Mar 2024
Reviewing Biostage (OTCMKTS:BSTG) and LENSAR (NASDAQ:LNSR) - American Banking and Market News

Tue, 18 Jul 2023
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease - PR Newswire

Tue, 13 Jun 2023
Biostage to Host Investor Call - June 13, 2023 - BioSpace

Wed, 28 Dec 2022
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer - PR Newswire

Mon, 08 Aug 2022
Biostage Announces Appointment of New Chief Financial Officer - Aug 08, 2022 - BioSpace

Tue, 30 Nov 2021
Biostage Hires David Green as Chief Executive Officer - BioSpace

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: PNK
Sector: Healthcare
Industry: Biotechnology
Shares Out	171 (M)
Shares Float	53 (M)
Held by Insiders	21 (%)
Held by Institutions	61.2 (%)
Shares Short	15,310 (K)
Shares Short P.Month	9,230 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-1.8 %
Operating Margin	2.6 %
Return on Assets (ttm)	1.6 %
Return on Equity (ttm)	-22.5 %
Qtrly Rev. Growth	20.5 %
Gross Profit (p.s.)	0
Sales Per Share	51.58
EBITDA (p.s.)	2.04
Qtrly Earnings Growth	0 %
Operating Cash Flow	211 (M)
Levered Free Cash Flow	239 (M)

PE Ratio	0
PEG Ratio	-1
Price to Book value	0
Price to Sales	0.2
Price to Cash Flow	8.75

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.